Volume : 09, Issue : 06, June – 2022
02.FORMULATION AND EVALUATION OF 5 FU LOADED EUDRAGIT MICROSPHERE FOR EFFECTIVE MANAGEMENT OF COLON CANCER
Anmol Kumar*, Ms. Mahak Jain, Mr. Pushpendra Kumar Khangar
5-Fluorouracil (5-FU) has a wide anticancer activity versus several types of solid tumors. The activity of 5-FU can be improved and its toxicity can be diminished by enhancing the relative specific accumulation in the tumor regions. The aim of this work was to develop Eudragit RS100 based 5-FU microsponges (MS) for treatment of colon cancer. Oil in oil emulsion solvent diffusion method was used for the preparation of 5-FU sustained release Eudragit RS100 MS. MS were characterized for their encapsulation efficiency, production yield, and drug release profiles. the mean particle size for Eudragit RS 100 was found in the range of 41.9±3.387 µm to 43.8±4.405 µm. As shown in the table the entrapment was less for Eudragit RS 100 and found in the range of 28.82 to 39.82 %. Methanol was used to dissolve the drug in all formulation and was an important factor that affects the production yield. The F3 was showed sustained release of drug up to 12 hours as compared to other formulations F1 and F2. The results demonstrated that 5-FU with Eudragit RS100 was successfully formulated as sustained release manner and could be a substitution delivery method of 5-FU for oral anticancer treatment.
Cite This Article:
Please cite this article in press Anmol Kumar et al, Formulation And Evaluation Of 5 FU Loaded Eudragit Microsphere For Effective Management Of Colon Cancer., Indo Am. J. P. Sci, 2022; 09(6).,
Number of Downloads : 10
1. C. Dhawale, A.S. Bankar, M.N. Patro, Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting, Int. J. Pharm. Tech. Res., 2 (2010), pp. 1112-1118
2. Ramesh K. Ramanathan, Jeffery W. Clark, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer Am. Soc. Clin. Oncol. (2003), pp. 2904-2911
3. Labianca R, Pessi MA, Zamparelli G, Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy, Drugs 53 (1997) 593–607.
4. 2. Van Cutsem E, Peeters M, Verslype C, The medical treatment of colorectal cancer: actual status and new developments, Hepatogastroenterology., 1999, 46, 709–716.
5. 3. Labianca RF, Beretta GD, Pessi MA, Disease management considerations: disease management considerations, Drugs., 2001, 61, 1751–1764.
6. 4. Krishnaiah YS, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS, In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil, Eur. J. Pharm. Sci., 2002, 16, 185–192.
7. 5. Madajewicz S, Petrelli N, Rustum YM, Phase I– II trial of high-dose calcium leucovorin and 5- fluorouracil in advanced colorectal cancer, Cancer Res., 1984, 44, 4667–4669.
8. 6. Cortesi E, Aschelter AM, Gioacchini N, Pellegrini A, Frati L, Ficorella C, Mazzei N, Marchetti P, Efficacy and toxicity of 5- fluorouracil and folates in advanced colon cancer, J. Chemother. 1990, 2, 47–50.
9. 7. O’Connell MJ, Mailliard JA, Kahn MJ, Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, J. Clin. Oncol. 1997, 15, 246–250.
10. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
11. Ismail IA, Kang KS, Lee HA, Kim JW, Sohn YK (2007) Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 upregulation and PLK1 down-regulation. Eur J Pharmacol 575: 12-20.
12. Sandor M, Enscore D, Weston P, Mathiowitz E (2001) Effect of protein molecular weight on release from micron-sized PLGA microspheres. J Control Release 76: 297-311.
13. Goto S, Kawata M, Nakamura M, Aoyama T (1985) Effect of magnesium stearate in preparation of eudragit RS-microcapsules containing drugs. Yakugaku zasshi: J Pharm Soci Japan 105: 1087-1095.
14. Arshady R (1991) Preparation of biodegradable microspheres and microcapsules: 2 Polyactides and related polyesters. J Control Release 17: 1-21.